Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib

Experimental Cell Research

Volumn 313, Issue 7, 2007, Pages 1361-1372

  Liu, Xuwan ^a   Carlisle, Diane L ^a   Swick, Michelle C ^a   Gaither Davis, Autumn ^a   Grandis, Jennifer R ^b   Siegfried, Jill M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Akt kinase; c Src kinase; EGFR; EGFR inhibitor; Gastrin releasing peptide; Gefitinib; Lung carcinoma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR; GASTRIN RELEASING PEPTIDE; GEFITINIB; NEUTRALIZING ANTIBODY; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ARTICLE; AUTOCRINE EFFECT; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; LUNG ALVEOLUS EPITHELIUM; LUNG NON SMALL CELL CANCER; MOLECULAR MIMICRY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 33947727520     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.01.016     Document Type: Article

References (47)

1. Casanueva F.F., Perez F.R., Casabiell X., Camina J.P., Cai R.Z., and Schally A.V. Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1406-1411
2. Emanuel R.L., Torday J.S., Mu Q., Asokananthan N., Sikorski K.A., and Sunday M.E. Bombesin-like peptides and receptors in normal fetal baboon lung: roles in lung growth and maturation. Am. J. Physiol. 277 (1999) L1003-L1017
3. al Moustafa A.E., Tsao M.S., Battey J.F., and Viallet J. Expression of the gastrin-releasing peptide receptor confers a growth response to bombesin in immortalized human bronchial epithelial cells. Cancer Res. 55 (1995) 1853-1855
4. Shriver S.P., Bourdeau H.A., Gubish C.T., Tirpak D.L., Davis A.L., Luketich J.D., and Siegfried J.M. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J. Natl. Cancer Inst. 92 (2000) 24-33
5. Moody T.W., Zia F., Venugopal R., Fagarasan M., Oie H., and Hu V. GRP receptors are present in non small cell lung cancer cells. J. Cell. Biochem.,Suppl. 24 (1996) 247-256
6. Siegfried J.M., Krishnamachary N., Gaither D.A., Gubish C., Hunt J.D., and Shriver S.P. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm. Pharmacol. Ther. 12 (1999) 291-302
7. Uchida K., Kojima A., Morokawa N., Tanabe O., Anzai C., Kawakami M., Eto Y., and Yoshimura K. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J. Cancer Res. Clin. Oncol. 128 (2002) 633-640
8. Cuttitta F., Carney D.N., Mulshine J., Moody T.W., Fedorko J., Fischler A., and Minna J.D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316 (1985) 823-826
9. Battey J.F., Way J.M., Corjay M.H., Shapira H., Kusano K., Harkins R., Wu J.M., Slattery T., Mann E., and Feldman R.I. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc. Natl Acad. Sci. U. S. A. 88 (1991) 395-399
10. Burghardt B., Wenger C., Barabas K., Racz G., Olah A., Flautner L., Coy D.H., Gress T.M., and Varga G. GRP-receptor-mediated signal transduction, gene expression and DNA synthesis in the human pancreatic adenocarcinoma cell line HPAF. Peptides 22 (2001) 1119-1128
11. Benya R.V., Akeson M., Mrozinski J., Jensen R.T., and Battey J.F. Internalization of the gastrin-releasing peptide receptor is mediated by both phospholipase C-dependent and -independent processes. Mol. Pharmacol. 46 (1994) 495-501
12. Qu X., Xiao D., and Weber H. Human gastrin-releasing peptide receptor mediates sustained CREB phosphorylation and transactivation in HuTu 80 duodenal cancer cells. FEBS Lett. 527 (2002) 109
13. Lui V.W., Thomas S.M., Zhang Q., Wentzel A.L., Siegfried J.M., Li J.Y., and Grandis J.R. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22 (2003) 6183-6193
14. Koh S.W., Leyton J., and Moody T.W. Bombesin activates MAP kinase in non-small cell lung cancer cells. Peptides 20 (1999) 121-126
15. Charlesworth A., and Rozengurt E. Bombesin and neuromedin B stimulate the activation of p42(mapk) and p74(raf-1) via a protein kinase C-independent pathway in Rat-1 cells. Oncogene 14 (1997) 2323-2329
16. Luttrell L.M., Hawes B.E., van Biesen T., Luttrell D.K., Lansing T.J., and Lefkowitz R.J. Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J. Biol.Chem. 271 (1996) 19443-19450
17. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13 (1999) 2905-2927
18. Hutchinson J., Jin J., Cardiff R.D., Woodgett J.R., and Muller W.J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol. Cell. Biol. 21 (2001) 2203-2212
19. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
20. Peso L.D., Gonzalez-Garcia M., Page C., Herrera R., and Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278 (1997) 687-689
21. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61 (2001) 3986-3997
22. Cappuzzo F., Magrini E., Ceresoli G.L., Bartolini S., Rossi E., Ludovini V., Gregorc V., Ligorio C., Cancellieri A., Damiani S., Spreafico A., Paties C.T., Lombardo L., Calandri C., Bellezza G., Tonato M., and Crino L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 96 (2004) 1133-1141
23. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
24. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
25. Zhang W., Stabile L.P., Keohavong P., Romkes M., Grandis J., Traynor A., and Siegfried J.M. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J. Thorac. Oncol. 1 (2006) 635-647
26. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J., and Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375 (1995) 577-581
27. Langer D.A., Kautzman D., and Kane M.A. Inhibition of proliferation of human small cell lung cancer cells expressing an autocrine system for gastrin releasing peptide by antisense oligodeoxynucleotides to gastrin releasing peptide receptor. Lung Cancer 36 (2002) 235-242
28. Bellacosa A., Chan T.O., Ahmed N.N., Datta K., Malstrom S., Stokoe D., McCormick F., Feng J., and Tsichlis P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17 (1998) 313-325
29. Datta K., Bellacosa A., Chan T.O., and Tsichlis P.N. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-Src and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem. 271 (1996) 30835-30839
30. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev., Cancer 2 (2002) 489-501
31. Thomas S.M., Grandis J.R., Wentzel A.L., Gooding W.E., Lui V.W., and Siegfried J.M. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 7 (2005) 426-431
32. Luttrell L.M., Della Rocca G.J., van Biesen T., Luttrell D.K., and Lefkowitz R.J. Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J. Biol. Chem. 272 (1997) 4637-4644
33. Testa J.R., and Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10983-10985
34. Kakiuchi S., Daigo Y., Ishikawa N., Furukawa C., Tsunoda T., Yano S., Nakagawa K., Tsuruo T., Kohno N., Fukuoka M., Sone S., and Nakamura Y. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa ZD1839). Hum. Mol. Genet. 13 (2004) 3029-3043
35. Ishikawa N., Daigo Y., Takano A., Taniwaki M., Kato T., Hayama S., Murakami H., Takeshima Y., Inai K., Nishimura H., Tsuchiya E., Kohno N., and Nakamura Y. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 65 (2005) 9176-9184
36. Lango M.N., Dyer K.F., Lui V.W., Gooding W.E., Gubish C., Siegfried J.M., and Grandis J.R. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J. Natl. Cancer Inst. 94 (2002) 375-383
37. Zhang Q., Thomas S.M., Xi S., Smithgall T.E., Siegfried J.M., Kamens J., Gooding W.E., and Grandis J.R. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 64 (2004) 6166-6173
38. Dikic I., Tokiwa G., Lev S., Courtneidge S.A., and Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 383 (1996) 547-550
39. Wu W., Graves L.M., Gill G.N., Parsons S.J., and Samet J.M. Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation. J. Biol. Chem. 277 (2002) 24252-24257
40. Zhang Q., Thomas S.M., Lui V.W., Xi S., Siegfried J.M., Fan H., Smithgall T.E., Mills G.B., and Grandis J.R. Phosphorylation of TNF-{alpha} converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6901-6906
41. Hurbin A., Coll J.L., Dubrez-Daloz L., Mari B., Auberger P., Brambilla C., and Favrot M.C. Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells. J. Biol. Chem. 280 (2005) 19757-19767
42. Lichtner R.B., Menrad A., Sommer A., Klar U., and Schneider M.R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 61 (2001) 5790-5795
43. Arteaga C.L., Ramsey T.T., Shawver L.K., and Guyer C.A. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J. Biol. Chem. 272 (1997) 23247-23254
44. Manley P.W., Bold G., Bruggen J., Fendrich G., Furet P., Mestan J., Schnell C., Stolz B., Meyer T., Meyhack B., Stark W., Strauss A., and Wood J. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697 (2004) 17-27
45. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289 (2000) 1938-1942
46. Hurbin A., Dubrez L., Coll J.L., and Favrot M.C. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J. Biol. Chem. 277 (2002) 49127-49133
47. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., Hamilton A.D., Polokoff M., Nicosia S.V., Herlyn M., Sebti S.M., and Cheng J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64 (2004) 4394-4399